About 10% of the World’s population (780 million people) suffers from various degrees of Dry Eye Disease (DED). This makes it the most common eye pathology.


i-Onion™ is focused on supporting early diagnosis and prediction of dry eye disease.

Our Added Value

Scientists involved in i-Onion™ development are in the forefront of world´s Dry Eye research.

The team​ patented an instrument and method to apply a brief pulse of CO2 gas on the corneal surface that activates sensory nerves, evoking maximal reflex secretion of tears by lacrimal glands.


reserve Detection of maximal tear secretion provides new information on the secretory reserve capacity of the lacrimal glands





OUR HISTORY



  • 2015ORIGINS

    Development of the scientific grounds of i-Onion™
  • 2019PATENTS & REGISTRATIONS

    Worldwide patent filings
  • 2020 (Q1)PRE-CLINICAL STUDIES & SCIENTIFIC PUBLICATIONS

    Publication in prestigious scientific journals
  • 2020 (Q2)α PROTOTYPE

    Creation and onset of testing trials
  • 2021 (Q1)COMPANY FOUNDATION

    Tearful Inc development & exclusive licensing from UMH/CSIC
  • 2021 (Q2)β PROTOTYPE

    Redesign and industrialization process & manufacturing of 5 Units
  • 2022 (Q1)DEMOSTRATION & INVESTMENTS

    β Prototype final testings & company capitalization process 1
  • 2022-23Sample Device Certification EU & INVESTMENTS

    Device self-certification process & company capitalization process 2
  • 2023Ongoing clinical partnerships

    Currently, our collaborators are studying use cases in different patients to obtain relevant clinical data that demonstrate the efficiency and relevance of the i-onion device.